Isabelle Van Praagh

1.5k total citations · 1 hit paper
23 papers, 908 citations indexed

About

Isabelle Van Praagh is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Isabelle Van Praagh has authored 23 papers receiving a total of 908 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Isabelle Van Praagh's work include Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (13 papers) and Breast Lesions and Carcinomas (6 papers). Isabelle Van Praagh is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (13 papers) and Breast Lesions and Carcinomas (6 papers). Isabelle Van Praagh collaborates with scholars based in France, United States and Switzerland. Isabelle Van Praagh's co-authors include P. Chollet, V. Servent, Hervé Curé, V. Feillel, G. Albrand, Christophe Desauw, Pierre Soubeyran, M. Rainfray, Hubert Rousselot and J Dauplat and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Isabelle Van Praagh

23 papers receiving 891 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study

2014 368 citations Pierre Soubeyran, Carine Bellera et al. PLoS ONE profile →

Peers

Countries citing papers authored by Isabelle Van Praagh

Since Specialization

Citations

This map shows the geographic impact of Isabelle Van Praagh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Van Praagh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Van Praagh more than expected).

Fields of papers citing papers by Isabelle Van Praagh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Van Praagh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Van Praagh. The network helps show where Isabelle Van Praagh may publish in the future.

Co-authorship network of co-authors of Isabelle Van Praagh

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Van Praagh. A scholar is included among the top collaborators of Isabelle Van Praagh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Van Praagh. Isabelle Van Praagh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments 2018 ·Clinical Breast Cancer ·Angeline Ginzac, Émilie Thivat, Marie‐Ange Mouret‐Reynier, Pascale Dubray‐Longeras, Isabelle Van Praagh, (unknown), Catherine Abrial, Fabrice Kwiatkowski, Yves Boirie‌, Martine Duclos, Béatrice Morio, Émilie Gadéa, Xavier Durando	4
2	Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line 2015 ·Oncology ·(unknown), Catherine Abrial, E. Planchat, Isabelle Van Praagh, (unknown), Fabrice Kwiatkowski, Pascale Dubray‐Longeras, (unknown), (unknown), Pauline Herviou, Hakim Mahammedi, Xavier Durando, P. Chollet, Marie‐Ange Mouret‐Reynier	3
3	Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study breakdown → 2014 ·PLoS ONE ·Pierre Soubeyran, Carine Bellera, (unknown), Damien Heitz, Hervé Curé, Hubert Rousselot, G. Albrand, V. Servent, O. Saint Jean, Isabelle Van Praagh, Jean‐Emmanuel Kurtz, (unknown), Jean-Luc Verhaeghe, C. Terret, Christophe Desauw, Véronique Girre, C. Mertens, Simone Mathoulin‐Pélissier, M. Rainfray	368
4	Everolimus Plus Hormonotherapy (Ht) Induces Survival Gain in Late Metastatic Breast Cancer (Mbc) After Progression: Could this Line Be Better Than a Late New Chemotherapy (Ct) Line? 2014 ·Annals of Oncology ·(unknown), E. Planchat, Catherine Abrial, Isabelle Van Praagh, (unknown), Fabrice Kwiatkowski, Pascale Dubray‐Longeras, (unknown), (unknown), Hakim Mahammedi, Xavier Durando, P. Chollet, Marie‐Ange Mouret‐Reynier	2
5	Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors 2012 ·Oncology ·Émilie Thivat, Isabelle Van Praagh, (unknown), Marie‐Ange Mouret‐Reynier, Fabrice Kwiatkowski, Xavier Durando, Hakim Mahammedi, Anne-Françoise Dillies, P. Chollet, (unknown)	18
6	Évaluation de l’observance des thérapeutiques orales en oncologie : résultats d’une étude pilote 2011 ·Journal de Pharmacie Clinique ·(unknown), Isabelle Van Praagh, P. Chollet, Annie Laurent, (unknown), Émilie Thivat	3
7	Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy 2010 ·Annals of Oncology ·Séverine Guiu, (unknown), Laure Favier, Isabelle Van Praagh, R. Largillier, B. Weber, David Coeffic, L. Moreau, Frank Priou, Mario Campone, Joseph Gligorov, Laurence Vanlemmens, V. Trillet-Lenoir, Laurent Arnould, Bruno Coudert	17
8	Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer 2009 ·Expert Opinion on Pharmacotherapy ·Jean‐Marc Nabholtz, Marie‐Ange Mouret‐Reynier, Xavier Durando, Isabelle Van Praagh, Sana Al‐Sukhun, Jean-Pierre Ferrière, P. Chollet	23
9	2134 POSTER Clinical benefit of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression 2007 ·European Journal of Cancer Supplements ·P. Chollet, Xavier Durando, L. Mauriac, Corinne Delcambre, P. Maillart, Corinne Veyret, Marie‐Ange Mouret‐Reynier, Isabelle Van Praagh, Thomas Bachelot	1
10	Gemcitabine oxaliplatin (GEMOX) is an active combination in heavily pretreated metastatic breast cancer (MBC) 2007 ·Journal of Clinical Oncology ·(unknown), (unknown), Marie‐Ange Mouret‐Reynier, Marianne Leheurteur, Isabelle Van Praagh, Xavier Durando, Jean-Pierre Ferrière, (unknown), P. Chollet	1
11	Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression 2007 ·Journal of Clinical Oncology ·Thomas Bachelot, L. Mauriac, Corinne Delcambre, P. Maillart, Corinne Veyret, M-A Mouret-Reynier, Isabelle Van Praagh, P. Chollet	5
12	[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer]. 2006 ·PubMed ·Marie‐Ange Mouret‐Reynier, Catherine Abrial, Marianne Leheurteur, Xavier Durando, Isabelle Van Praagh, Pierre Gimbergues, J.L. Achard, Jean-Pierre Ferrière, Hervé Curé, P. Chollet	2
13	Pathological and Clinical Response of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Paclitaxel as Neoadjuvant Treatment in Patients with Operable Breast Cancer 2005 ·The Oncologist ·Catherine Abrial, Isabelle Van Praagh, R. Delva, Bernard Leduc, Joël Fleury, Érick Gamelin, (unknown), Frédérique Penault‐Llorca, S. Amat, P. Chollet	9
14	Pre- and Postoperative Aminoacidemia in Breast Cancer: A Study vs. Matched Healthy Subjects 2004 ·Cancer Investigation ·Régine Minet‐Quinard, Isabelle Van Praagh, Fabrice Kwiatkowski, (unknown), V. Feillel, B. Beaufrère, (unknown), Luc Cynober, Marie‐Paule Vasson	11
15	Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial 2004 ·Journal of Clinical Oncology ·P. Fargeot, Jacques Bonneterre, Henri Roché, Alain Lortholary, Mario Campone, Isabelle Van Praagh, Alain Monnier, Moïse Namer, S Schraub, (unknown), Jean‐Paul Guastalla, Marie-Josèphe Goudier, (unknown)	82
16	Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy 2002 ·International Journal of Oncology ·S. Amat, Frédérique Penault‐Llorca, H. Curé, G. Le Bouëdec, J.L. Achard, Isabelle Van Praagh, V. Feillel, M-A Mouret-Reynier, J Dauplat, P. Chollet	83
17	Efficacy of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Methotrexate (VEM) as Neoadjuvant Treatment in 89 Patients with Operable Breast Cancer 2002 ·The Oncologist ·Isabelle Van Praagh, Hervé Curé, Bernard Leduc, Sabine Charrier, G. Le Bouëdec, J.L. Achard, Jean-Pierre Ferrière, V. Feillel, (unknown), J Dauplat, P. Chollet	15
18	Vinorelbine, Epirubicin, and Methotrexate (VEM) as Primary Treatment in Locally Advanced Breast Cancer 2001 ·The Oncologist ·Jitka Abrahámová, M Wagnerová, Eugen Kubala, (unknown), Е. Симова, (unknown), Е.П. Павликова, (unknown), Ivo Kocák, (unknown), Paula Tuma, Jana Prausová, (unknown), Isabelle Van Praagh	6
19	Clinical and pathological response to primary chemotherapy in operable breast cancer 1997 ·European Journal of Cancer ·P. Chollet, Sabine Charrier, Étienne Brain, H. Curé, Isabelle Van Praagh, V. Feillel, M de Latour, J Dauplat, J. L. Misset, Jean-Pierre Ferrière	92
20	[First-line chemotherapy in operable breast neoplasms: results of 3 protocols]. 1997 ·PubMed ·Hervé Curé, Sabine Charrier, (unknown), Isabelle Van Praagh, (unknown), (unknown), M de Latour, J.-O. Bay, J.L. Achard, J Dauplat, P. Chollet	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact